AQUESTIVE THERAPEUTICS INC (AQST)

Company Profile

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 130 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The firm has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place. Its active programs in its complex molecule pipeline portfolio are: AQST-109-SF and AQST-108-SF. AQST-109-SF (sublingual film) is an orally delivered epinephrine product candidate. AQST-108 is composed of the prodrug dipivefrin which is enzymatically cleaved into epinephrine after administration. Its CNS product candidate, Libervant, is an administered soluble film formulation of diazepam and is its advanced proprietary investigational product candidate. Its licensed products include Suboxone, Exservan, and KYNMOBI.

Company Info

AQUESTIVE THERAPEUTICS INC

30 Technology Dr

WARREN NEW JERSEY 07059

P: 19089411900

CEO: Keith J. Kendall

Employees: 130

Website: https://aquestive.com/